Suppose a new treatment for Parkinson's disease presented itself.
Hypothetical clinical studies suggests the general benefits:
1) Symptom regression of 1-4 years for 94% of the study population (cognitive and motor). 6% experience little to no symptom regression. Those who are recently diagnosed or experience minimal PD symptoms can often eliminate PD symptoms entirely.
2) PD progression slows down 90-98% for 92% of the PD population.
3) Most results are experienced in the first 10-30 days, and maximize after 6 months.
Ongoing treatment involves taking a total of 17 pills divided over four times a day (5 + 4 + 4 + 4) and moderate exercise at least 3 times per week.
The most common side effect being initial diarrhea (22%) for the first four weeks; heartburn is experienced for 9% of the population. Symptoms are further mitigated when dosages are taken with food.
Assume long term safety of at least 20+ years is clinically established.
If production, packaging, and marketing costs would allow such to be available for under $200 per month would that be of interest.
Why, or why not.
(as an FYI, this product does not exist so please do not ask where it can be found)
Written by
JonCR
To view profiles and participate in discussions please or .
Why or why not what? For a PD patient to do it? Yes, of course they should do it. Why or why not will it be invented before we die? Probably not because in the past 30 years treatment has gained only about 1/4 of what you describe. Singularity fans say we might be downloading our brains to work on computers in the next 30 years, so yes, anything is possible.
$200 a month to be converted from a zombie into someone who is alive seems amazingly inexpensive. It means the difference between sitting around all day thinking about suicide verses working at a job you love. Keep in mind everyone able to post a message here are in the better 50% of the cases, less depressed and more functional by far than many cases. What percent of PD patients end up in nursing homes? $200 a month working at a job you love verses being in a nursing home or otherwise mooching the life's blood (time and money) out of your children and grandchildren's future seems like an easy choice. The standard first-line drug in early cases (rasagiline) is $400 a month in the U.S. (but $50 a year in India if you happen to fly there, have a friend, or find a trustworthy web site.) What is the cost of DBS? $50,000?
But remember it would only stop or nearly stop PD progression. If one is already a "PD zombie" then they might gain some symptom relief, but they would still have PD symptoms...it would just not progress any further.
Those who have less advanced PD symptoms might be able to eliminate PD symptoms all together, even without Sinemet.
But, those are all good points worth of considering.
My degree of interest would depend on the confidence I had in the results posted and whether I can get the same or better improvement elsewhere. For instance, are the claimed results from a double blind trial? does the therapy fit a recognised theory of PD's pathogenesis? is the product non-profit making? is the improvement additive with existing medication (e.g. levodopa, rasagiline, ropinorole)? If all these conditions were met, $200/month would be OK.
The product would be for profit. Study is double blind placebo controlled. There are no other known ways to stop PD progression. Existing medications typical to PD have no known conflicts. Persons with gallstones should not take the product till gallstones are addressed.
That works VERY well. It has been recently improved upon...with choline, omega 3, and uridine...for synaptic biogenesis...now it helps better dealing with anxiety and lack of focus. The MCT oil is not necessary. PQQ is still recommended, but it is quite expensive.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.